The UK has an incredible opportunity to improve patients’ lives through cannabis-based medicines for some of the most debilitating conditions, such as chronic pain. Celadon Pharmaceuticals Plc is at the forefront of building this new pharmaceutical sector. We have a simple approach: high-quality UK cultivation and API manufacturing, clinical trials, and R&D into cannabinoids. We …
For those leading the company, this has been a very personal mission to produce a high-quality trial for cannabis-based medicines. James Short (CEO and co-founder of Celadon Pharmaceuticals Plc) saw his sister’s experience of living with multiple sclerosis for years and also witnessed first-hand the potential benefits of cannabis-based medicines for her condition. James also …
Celadon Pharmaceuticals Plc’s CEO Jim Short featured discussing the new MHRA framework for UK domestic production of cannabis-based medicines. Celadon was proudly a pioneer in working with the regulators back in 2019-2020. The new framework indicates a truly pharmaceutical direction of travel for the UK. This is Celadon’s approach: pharma-grade products, breakthrough R&D and clinical …
Today Celadon announced its Interim Results for the six months ended 30 June 2022, a period of considerable development and growth for the company. Highlights include: – The completion of seven harvests of high THC cannabis – Formally requesting that the MHRA schedule an inspection of our facility for our GMP licence – The commencement …
Celadon has been published in the Birmingham Mail on 30th July 2022. Click here to read the full story.
We are delighted to feature in BusinessCann today. Read the full article here: https://businesscann.com/celadon-pharma-says-it-wants-to-deliver-its-trial-and-product-as-a-holistic-package-overseas-amid-first-update-since-aim-listing/
London, UK, 22 June 2022: Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the development and supply of natural, cannabis-based medicines, is pleased to announce an update on its business and operations following the Company’s Admission to AIM on 28 March 2022. Highlights Successfully completed sixth harvest from its Phase 1 grow …
Read the Express news article full story There has been a new article published in the Express newspaper today about how one of Celadon’s subsidiary companies LVL Health‘s game-changing trial is providing the best data set to date in the UK for the use of cannabis-based medicines for chronic pain. Celadon Pharmaceuticals Plc is the …
Listen to the podcaste on Spotify Here is a great short podcast with Celadon Pharmaceuticals Plc CEO James Short explaining how pharma-grade cannabis-based medicines might help the 8 million adults with untreatable chronic pain in the UK, and why the UK is uniquely placed to build a burgeoning industry. Fresh off becoming the only AIM-listed cannabinoid …
Celadon Pharmaceuticals Plc is proud to be featured in The Guardian newspaper today with a story titled “Inside one of the first licenced medical cannabis labs in Britain“. Click here to read the full story.
Input your search keywords and press Enter.